Intomics: Zealand Pharma to leverage Intomics bioinformatics platform within peptide drug discovery and development process

Press Release - No. 07 / 2020Zealand Pharma to leverage Intomics bioinformatics platform within peptide drug discovery and development processThe research agreement enhances Zealand Pharma's ability to use 'Big Data', artificial intelligence and machine learning in the discovery and development of next generation peptide therapeutics From its competences within AI, machine learning, and network biology, Intomics has developed the inBio platform, which has been successfully used for accelerating R&D, including identification of novel targets, discovery of biomarkers, patient stratification, and precision medicineCopenhagen, June 10, 2020 - Zealand Pharma A/S (NASDAQ:ZEAL) (CVR-no. 20045078), a biotechnology company changing lives with innovative peptide-based medicines, today announced a two-year research agreement with Intomics A/S to focus on using integrated bioinformatics and systems biology to complement Zealand's early pipeline activities.Built on more than 20 years of expertise in the discovery and development of peptide therapeutics, Zealand is increasing use of artificial intelligence and machine learning as tools to power integration of clinical, biological and chemical data to explore new drug targets and pathways.For more than a decade, Intomics has worked closely with a wide range ...Full story available on Benzinga.com